CL2017001479A1 - Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1 - Google Patents
Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1Info
- Publication number
- CL2017001479A1 CL2017001479A1 CL2017001479A CL2017001479A CL2017001479A1 CL 2017001479 A1 CL2017001479 A1 CL 2017001479A1 CL 2017001479 A CL2017001479 A CL 2017001479A CL 2017001479 A CL2017001479 A CL 2017001479A CL 2017001479 A1 CL2017001479 A1 CL 2017001479A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical combination
- selective
- receptor agonist
- methyl
- dioate
- Prior art date
Links
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- JDOZUYVDIAKODH-SNAWJCMRSA-N 4-o-ethyl 1-o-methyl (e)-but-2-enedioate Chemical compound CCOC(=O)\C=C\C(=O)OC JDOZUYVDIAKODH-SNAWJCMRSA-N 0.000 abstract 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
Abstract
<p>LA PRESENTE INTENCIÓN SE RELACIONA CON UNA COMBINACIÓN FARMACÉUTICA COMPRENDIENDO UN PRIMER INGREDIENTE ACTIVO QUE ES (R)-5-[3- CLORO-4-(2,3-DIHIDROXI-PROPOXI)-BENZ[Z]ILIDEN]-2-([Z]PROPILIMINO)-3-O-TOTIL-TIAZOLIDIN-4-ONA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO Y UN SEGUNDO INGREDIENTE ACTIVO EL CUAL ES SELECCIONADO DEL GRUPO CONSISTENTE DE METIL FUMARATO, DIMETIL FUMARATO, (N,N-DIETILCARBAMOIL)METIL METIL (2E)BUT-2-EN-1 ,4-DIOATO, Y 2-(2,5-DIOXOPIRROLIDIN-1-IL)ETIL METIL (2E)BUT-2-EN-1 ,4-DIOATO, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2014077469 | 2014-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001479A1 true CL2017001479A1 (es) | 2018-02-09 |
Family
ID=54848562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001479A CL2017001479A1 (es) | 2014-12-11 | 2017-06-09 | Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US10245253B2 (es) |
| EP (2) | EP3229794B1 (es) |
| JP (3) | JP6437119B2 (es) |
| KR (3) | KR20190077131A (es) |
| CN (1) | CN106999462B (es) |
| AU (1) | AU2015359306B2 (es) |
| BR (1) | BR112017012396B1 (es) |
| CA (1) | CA2964616C (es) |
| CL (1) | CL2017001479A1 (es) |
| CY (1) | CY2022011I2 (es) |
| EA (2) | EA039629B1 (es) |
| HK (1) | HK1245106A1 (es) |
| HR (1) | HRP20251463T1 (es) |
| IL (2) | IL252701B (es) |
| MA (2) | MA41139A (es) |
| MX (2) | MX2021005516A (es) |
| PH (1) | PH12017501060B1 (es) |
| SA (1) | SA517381489B1 (es) |
| SG (1) | SG11201704569SA (es) |
| SM (1) | SMT202500469T1 (es) |
| UA (1) | UA122063C2 (es) |
| WO (1) | WO2016092042A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2278960T2 (sl) | 2008-03-17 | 2020-02-28 | Actelion Pharmaceuticals Ltd. | Režim odmerjanja za selektivni agonist receptorja sip1 |
| MA41139A (fr) * | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| MX379273B (es) | 2014-12-11 | 2025-03-11 | Actelion Pharmaceuticals Ltd | Regimen de dosificación para un agonista selectivo de receptor s1p1. |
| JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| EP4146190A2 (en) * | 2020-05-06 | 2023-03-15 | Imcyse SA | Combination treatment for fumarate-related diseases |
| WO2022223778A1 (en) * | 2021-04-23 | 2022-10-27 | Helmholtz-Zentrum für Infektionsforschung GmbH | Citraconic acid and derivatives thereof for use as a medicament |
| KR20230120768A (ko) | 2022-02-10 | 2023-08-17 | 하나 영농조합법인 | 양념 핫소스와 그 제조방법 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
| US7538135B2 (en) | 2003-07-08 | 2009-05-26 | Novartis Ag | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds |
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| RU2379299C2 (ru) | 2003-11-21 | 2010-01-20 | Актелион Фармасьютиклз Лтд | Производные 5-(бенз-(z)-илиден)тиазолидин-4-она и их применение в качестве иммуносупрессорных агентов |
| US7718704B2 (en) | 2004-02-24 | 2010-05-18 | Irm Llc | Immunosuppressant compounds and compositions |
| ES2582942T3 (es) | 2004-10-08 | 2016-09-16 | Forward Pharma A/S | Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico |
| KR20150028858A (ko) | 2004-11-29 | 2015-03-16 | 노파르티스 아게 | Ｓ１ｐ 수용체 효능제의 투여 용법 |
| US7879821B2 (en) | 2006-01-26 | 2011-02-01 | University Of Medicine And Dentistry Of New Jersey | Method for modulating inflammatory responses by altering plasma lipid levels |
| MX2009005048A (es) | 2006-11-23 | 2009-05-25 | Actelion Pharmaceuticals Ltd | Nuevo proceso para la preparacion de derivados de 2-imino-tiazolidin-4-ona. |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| SI2653873T1 (sl) | 2007-02-08 | 2022-09-30 | Biogen Ma Inc. | Sestave in načini uporabe za zdravljenje multiple skleroze |
| SI2278960T2 (sl) | 2008-03-17 | 2020-02-28 | Actelion Pharmaceuticals Ltd. | Režim odmerjanja za selektivni agonist receptorja sip1 |
| US8148414B2 (en) * | 2008-08-19 | 2012-04-03 | Xenoport, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| EP2177521A1 (en) | 2008-10-14 | 2010-04-21 | Almirall, S.A. | New 2-Amidothiadiazole Derivatives |
| GB0819182D0 (en) * | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| US20100160369A1 (en) | 2008-12-04 | 2010-06-24 | Exelixis, Inc. | S1P1 Agonists and Methods of Making And Using |
| MX367667B (es) | 2008-12-22 | 2019-08-30 | Novartis Ag | Régimen de dosificación de un agonista de los receptores de s1p. |
| DK4098256T5 (da) | 2008-12-22 | 2025-07-21 | Novartis Ag | Doseringsregime for en s1p-receptoragonist |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| HUE030169T2 (en) | 2009-01-09 | 2017-05-29 | Forward Pharma As | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| DE102010048788A1 (de) | 2009-02-13 | 2011-05-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| DE102009008851A1 (de) | 2009-02-13 | 2010-08-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| US20100260755A1 (en) | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
| EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
| DE112010004626T5 (de) | 2009-12-01 | 2012-10-18 | Metanomics Health Gmbh | Mittel und Verfahren zur Diagnose von multipler Sklerose |
| EP2343287A1 (en) | 2009-12-10 | 2011-07-13 | Almirall, S.A. | New 2-aminothiadiazole derivatives |
| DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
| EP2366702A1 (en) | 2010-03-18 | 2011-09-21 | Almirall, S.A. | New oxadiazole derivatives |
| EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| EP2455080A1 (en) | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
| EP2713724A4 (en) * | 2011-05-26 | 2015-03-11 | Biogen Idec Inc | METHODS OF TREATING MULTIPLE SCLEROSIS AND PRESERVING AND / OR INCREASING MYELINE CONTENT |
| EP2715361A1 (en) | 2011-05-31 | 2014-04-09 | Metanomics Health GmbH | Methods for diagnosing multiple sclerosis |
| CN113244185A (zh) | 2012-02-07 | 2021-08-13 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| US20130314669A1 (en) | 2012-05-24 | 2013-11-28 | Hadasit Medical Research Services And Development Ltd. | Method and system for assessing visual disorder |
| CN104684560B (zh) | 2012-07-27 | 2018-08-17 | 比奥根艾迪克Ma公司 | 作为s1p调节剂和/或atx调节剂的化合物 |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| WO2014025709A1 (en) | 2012-08-06 | 2014-02-13 | Biogen Idec Ma Inc. | Compounds that are s1p modulating agents and/or atx modulating agents |
| US10273234B2 (en) | 2012-08-06 | 2019-04-30 | Biogen Ma Inc. | Compounds that are S1P modulating agents and/or ATX modulating agents |
| WO2014028299A1 (en) | 2012-08-13 | 2014-02-20 | Biogen Idec Ma Inc. | Disease progression parameters and uses thereof for evaluating multiple sclerosis |
| RS60408B1 (sr) | 2012-08-17 | 2020-07-31 | Actelion Pharmaceuticals Ltd | Postupak za pripremanje (2z,5z)-5-(3-hloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međujedinjenja upotrebljena u pomenutom postupku |
| AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| WO2014031844A1 (en) * | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| CN104870014A (zh) | 2012-10-09 | 2015-08-26 | 比奥根Ma公司 | 联合治疗及用于治疗脱髓鞘病症的用途 |
| WO2014071371A1 (en) * | 2012-11-05 | 2014-05-08 | Xenoport, Inc. | Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate |
| PT2970101T (pt) | 2013-03-14 | 2018-10-04 | Alkermes Pharma Ireland Ltd | Pró-fármacos de fumaratos e seu uso no tratamento de várias doenças |
| US8669281B1 (en) * | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| US20170165236A1 (en) | 2013-11-01 | 2017-06-15 | Celgene International Ii Sàrl | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| MX379273B (es) | 2014-12-11 | 2025-03-11 | Actelion Pharmaceuticals Ltd | Regimen de dosificación para un agonista selectivo de receptor s1p1. |
| MA41139A (fr) * | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
-
2015
- 2015-12-09 MA MA041139A patent/MA41139A/fr unknown
- 2015-12-10 MX MX2021005516A patent/MX2021005516A/es unknown
- 2015-12-10 MX MX2017007651A patent/MX382489B/es unknown
- 2015-12-10 SM SM20250469T patent/SMT202500469T1/it unknown
- 2015-12-10 BR BR112017012396-7A patent/BR112017012396B1/pt active IP Right Grant
- 2015-12-10 EA EA201791260A patent/EA039629B1/ru unknown
- 2015-12-10 EP EP15808184.4A patent/EP3229794B1/en active Active
- 2015-12-10 EA EA202290017A patent/EA202290017A1/ru unknown
- 2015-12-10 AU AU2015359306A patent/AU2015359306B2/en active Active
- 2015-12-10 MA MA41481A patent/MA41481B1/fr unknown
- 2015-12-10 UA UAA201707085A patent/UA122063C2/uk unknown
- 2015-12-10 HK HK18104570.0A patent/HK1245106A1/zh unknown
- 2015-12-10 EP EP25194913.7A patent/EP4620526A3/en active Pending
- 2015-12-10 SG SG11201704569SA patent/SG11201704569SA/en unknown
- 2015-12-10 CA CA2964616A patent/CA2964616C/en active Active
- 2015-12-10 HR HRP20251463TT patent/HRP20251463T1/hr unknown
- 2015-12-10 KR KR1020197018384A patent/KR20190077131A/ko not_active Ceased
- 2015-12-10 KR KR1020217030568A patent/KR20210122315A/ko not_active Ceased
- 2015-12-10 JP JP2017531166A patent/JP6437119B2/ja active Active
- 2015-12-10 US US15/534,951 patent/US10245253B2/en active Active
- 2015-12-10 KR KR1020177019100A patent/KR101996245B1/ko active Active
- 2015-12-10 WO PCT/EP2015/079311 patent/WO2016092042A1/en not_active Ceased
- 2015-12-10 CN CN201580067625.2A patent/CN106999462B/zh active Active
-
2017
- 2017-05-09 SA SA517381489A patent/SA517381489B1/ar unknown
- 2017-06-06 IL IL252701A patent/IL252701B/en unknown
- 2017-06-07 PH PH12017501060A patent/PH12017501060B1/en unknown
- 2017-06-09 CL CL2017001479A patent/CL2017001479A1/es unknown
-
2018
- 2018-09-20 JP JP2018176173A patent/JP6846392B2/ja active Active
-
2019
- 2019-02-15 US US16/277,829 patent/US11026927B2/en active Active
-
2020
- 2020-12-23 JP JP2020213525A patent/JP7033642B2/ja active Active
-
2021
- 2021-05-20 US US17/325,912 patent/US11672783B2/en active Active
- 2021-12-12 IL IL288907A patent/IL288907A/en unknown
-
2022
- 2022-05-10 CY CY2022011C patent/CY2022011I2/el unknown
-
2023
- 2023-05-11 US US18/315,954 patent/US12409167B2/en active Active
-
2024
- 2024-01-02 US US18/401,886 patent/US20240131009A1/en not_active Abandoned
-
2025
- 2025-08-15 US US19/301,469 patent/US20250375426A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001479A1 (es) | Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1 | |
| NO2022023I1 (no) | Ponesimod (IUPAC name: (R)-5-[3-chloro-4-(2,3-dih ydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolylthiazolidin-4-one) and harmaceutically acceptable salts thereof | |
| EP3256149A4 (en) | FORMULATION FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES | |
| WO2015054500A3 (en) | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| UY36761A (es) | Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma | |
| CO2018001383A2 (es) | Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp” | |
| MX2016014946A (es) | Derivados de carboxamida. | |
| MA40781A (fr) | Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale | |
| EA201890896A1 (ru) | Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения | |
| FR3005411B1 (fr) | Association d'actifs pour une administration par voie orale pour ameliorer la qualite des ongles. | |
| PH12016502527B1 (en) | Stabilized desmopressin | |
| CU20160170A7 (es) | Derivados de carboxamida | |
| ZA201803722B (en) | Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof | |
| TH169595A (th) | การใช้เซอร์โลพิแทนต์ซึ่งเป็นnk-1 รีเซพเตอร์แอนทาโกนิสต์ ในอาการคัน | |
| FR3031676B1 (fr) | Composition cosmetique pour administration par voie orale pour renforcer la barriere cutanee. |